A Study of HRS2543 in Patients With Advanced Tumors

Updated 06/21/2024

Status Recruiting

Clinical Trial Summary

To assess the safety and tolerability of HRS2543 in patients with advanced tumors and to determine the recommended phase II dose (RP2D) of HRS2543

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Advanced Tumors

Clinical Trial Details

NCT number	NCT05068856
Study type	Interventional
Source	Shanghai Hengrui Pharmaceutical Co., Ltd.
Contact	Jie Xie, M.M.
Phone	+021-61053363
Email	jie.xie@hengrui.com
Status	Recruiting
Phase	Phase 1
Start date	December 28, 2021
Completion date	August 31, 2023

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT06245122` - A Study of CS23546 in Subjects With Advanced Tumors	Phase 1
	Not yet recruiting	`NCT06314087` - iTAPVR Study - Phase II Randomized Study	Phase 2
	Recruiting	`NCT05390528` - A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma	Phase 1/Phase 2
	Completed	`NCT02419417` - Study of BMS-986158 in Subjects With Select Advanced Cancers	Phase 1/Phase 2
	Completed	`NCT04808453` - Phase I Study of CPI-300 in Patients With Advanced Tumors	Phase 1
	Recruiting	`NCT05799183` - A SHR-1210 BE Study on Healthy Subjects	Phase 1
	Recruiting	`NCT05429008` - A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm	Phase 1
	Terminated	`NCT04198818` - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors	Phase 1/Phase 2
	Not yet recruiting	`NCT05213767` - Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors	Phase 1
	Not yet recruiting	`NCT04151810` - Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors	Phase 1
	Completed	`NCT03781362` - Study of CPI-100 in Patients With Advanced Tumors	Phase 1
	Recruiting	`NCT03908814` - Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors	Phase 1
	Recruiting	`NCT05061628` - The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor	Phase 1
	Recruiting	`NCT05867771` - A Study of PM1022 in Patients With Advanced Tumors	Phase 1/Phase 2
	Recruiting	`NCT03444714` - Phase I Study of RiMO-301 With Radiation in Advanced Tumors	Phase 1